Please login to the form below

Not currently logged in
Email:
Password:

Yondelis

This page shows the latest Yondelis news and features for those working in and with pharma, biotech and healthcare.

Lilly snags first approval for sarcoma drug Lartruvo

Lilly snags first approval for sarcoma drug Lartruvo

Another drug - Johnson &Johnson's Yondelis (trabectedin) - was approved in 2015 for two specific types of STS (liposarcoma and leiomyosarcoma).

Latest news

  • Lilly closes on first approval for sarcoma drug Lartruvo Lilly closes on first approval for sarcoma drug Lartruvo

    If approved, the drug will join other new therapies for STS, including Johnson &Johnson's chemotherapy agent Yondelis (trabectedin) and Eisai's Halaven (eribulin mesylate), both of which have been approved

  • NICE recommends two drugs for ovarian cancer but rejects three NICE recommends two drugs for ovarian cancer but rejects three

    But the cost-effectiveness body rejected GlaxoSmithKline's Hycamtin (topotecan), PharmaMar's Yondelis (trabectedin) and Lilly's Gemzar (gemcitabine) for treating the first recurrence of platinum-sensitive ovarian cancer.

  • Novartis curates interactive history of medicine exhibition Novartis curates interactive history of medicine exhibition

    Another firm active in this space is Pharma Mar, whose marine-derived antitumoral agent Yondelis (trabectedin) received US approval last month to treat unresectable or metastic liposarcoma or leiomyosarcoma. .

  • FDA approves Janssen’s Yondelis FDA approves Janssen’s Yondelis

    The US approval comes on the back of data from a phase III trial which evaluated Yondelis (trabectedin) versus dacarbazine. ... However, Yondelis showed a significant improvement in progression-free survival of 4.2 months versus dacarbazine's 1.5 months.

  • PharmaMar/J&J’s Yondelis fast-tracked by FDA for sarcoma PharmaMar/J&J’s Yondelis fast-tracked by FDA for sarcoma

    Cancer drug could be approved in the US within months. PharmaMar's cancer drug Yondelis could be approved in the US within a few months after it was fast-tracked by ... We are particularly proud of this filing, as it represents our commitment to Yondelis

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics